Methylphenidate Hydrochloride Extended Release
Brand Names: Methylphenidate Hydrochloride Extended Release Generic
Methodology & AI Transparency ⓘ
Methylphenidate Hydrochloride Extended Release Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Methylphenidate hydrochloride extended-release tablets are indicated for the treatment of: ; Attention Deficit Hyperactivity Disorders (ADHD) in pediatric patients 6 years and older and adults ; Narcolepsy Limitations of Use: The use of Methylphenidate hydrochloride is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage .
- 2 Real-world patient consensus: Real-world cohort score of 83% across 11 de-identified Methylphenidate Hydrochloride Extended Release entries.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $26.22 cash mean against $64.24 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Methylphenidate Hydrochloride Extended Release tolerability events: nausea (7.6%), headache (6.6%), dizziness (5.9%).
Ask our AI Specialists anything about Methylphenidate Hydrochloride Extended Release
Methylphenidate Hydrochloride Extended Release Mechanism, CYP450 Pathways & DailyMed Monograph
Methylphenidate hydrochloride extended-release tablets are indicated for the treatment of: ; Attention Deficit Hyperactivity Disorders (ADHD) in pediatric patients 6 years and older and adults ; Narcolepsy Limitations of Use: The use of Methylphenidate hydrochloride is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage .
12.1 Mechanism of Action Methylphenidate hydrochloride is a CNS stimulant. The mode of therapeutic action in ADHD and narcolepsy is not known. 12.2 Pharmacodynamics Methylphenidate is a racemic mixture comprised of the d- and l-threo enantiomers. The d-threo enantiomer is more pharmacologically active than the l-threo enantiomer. Methylphenidate blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.
Following administration (10 mg/1 Tablet), Methylphenidate Hydrochloride Extended Release achieves Approximately 75% to 87% enteral uptake across labeled Methylphenidate Hydrochloride Extended Release strengths bioavailability and maximum serum exposure occurs 2–4 hours after methylphenidate hydrochloride extended release dosing onset, governed by a Steady-state plasma equilibrium reached over 3–12 hour t½ intervals for Methylphenidate Hydrochloride Extended Release terminal half-life through predominantly hepatic biotransformation with renal elimination of polar methylphenidate hydrochloride extended release conjugates.
Before initiating Methylphenidate Hydrochloride Extended Release at 10 mg/1 Tablet, clinical safety checklists rule out 4 contraindications; hypersensitivity to methylphenidate or other components of methylphenidate hydrochloride extended-release tablets.; hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported in patients treated with methylphenidate .. Logged tolerability patterns center on nausea (7.6% of reports), headache (6.6% of reports), dizziness (5.9% of reports).
Verify medication reconciliation lists so Methylphenidate Hydrochloride Extended Release is not inadvertently duplicated with another central nervous system stimulant.
Unstandardized herbal extracts may interact pharmacodynamically with Methylphenidate Hydrochloride Extended Release maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS
- Hypersensitivity to methylphenidate or other components of Methylphenidate hydrochloride extended-release tablets.
- Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported in patients treated with methylphenidate .
Logged Side-Effect Incidence (11 Reports)
Methylphenidate Hydrochloride Extended Release Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Methylphenidate Hydrochloride Extended Release)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate The measurements used for the assessment of apathy in patients with AD had a high degree of overlap with the DCA. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry • 2021-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 32565008 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Trimodal Dexmethylphenidate (CTx-1301) in Children and CTx-1301 demonstrated dose-related improvements in signs and symptoms of ADHD, although statistical significance is not consistent across all dose groups. Journal of child and adolescent psychopharmacology • 2026-12-15 • Phase III Randomized Trial | N = 103 | 88/100 | PMID 42484049 ↗ |
| Can This Approach Help? Inside the Latest Research on A Randomized, Phase 3, gold-standard blind, Crossover Comparison of Multilayer, PRC-063 and LDX had comparable effects on driving performance, from 1 through 15 hours, the last time point measured. Journal of attention disorders • 2024-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38404033 ↗ |
| Can This Approach Help? Inside the Latest Research on A Post-Hoc Analysis of Emotional Lability With Delayed-Release/Extended-Release DR/ER-MPH treatment resulted in statistically significant improvements in EL to the level of non-ADHD peers as contextualized by T -scores. Journal of attention disorders • 2024-06-15 • Phase III Randomized Trial | N = 117 | 88/100 | PMID 38600754 ↗ |
| Can This Approach Help? Inside the Latest Research on Symptomatic and Functional Response and full symptom relief From the Open-Label More participants starting on a 40-mg versus 20-mg dose achieved thresholds at week 1 ( P Conclusions: When DR/ER-MPH dosing was optimized for ADHD symptom control throughout the. The Journal of clinical psychiatry • 2021-06-22 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34166587 ↗ |
Methylphenidate Hydrochloride Extended Release Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.4374/unit (~$13.12/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $64.24 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 11 Anonymous DotMD Community Micro-Logs | $26.22 / mo | View logs ↓ |
Methylphenidate Hydrochloride Extended Release Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Methylphenidate Hydrochloride Extended Release RxNorm Concept ID | 1091145 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.4374 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $64.24 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $26.22 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 83.00% Worth It (11 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Methylphenidate Hydrochloride Extended Release Patient Community, Cohort Filters & Dosage Logs
Cross-verified Methylphenidate Hydrochloride Extended Release (central nervous system stimulant) monograph synthesizing RxNorm 1091145, openFDA FAERS signals, and $26.22–$64.24 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Methylphenidate Hydrochloride Extended Release community threads and patient logs by age, biological sex, dosage, and treatment duration.